Preeclampsia Risk Evaluation for 2nd and 3rd Trimester-994

Test info

  
Preeclampsia Risk Evaluation for 2nd and 3rd Trimester
  
994
  
LAB994
  
MSO
  
Preeclampsia Predictor
Pre-eclampsia
SFLT
PLGF
SFLT/PLFG Ratio
  

Aiding in the risk assessment of pregnant women (singleton pregnancies between gestational age 23+0 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) for progression to preeclampsia with severe features (as defined by American College of Obstetricians (ACOG) guidelines) within two weeks of presentation.

  
  • The results of the test are not intended for making a diagnosis of preeclampsia or preeclampsia with severe features.
  • The results of the test are not a stand-alone test for monitoring of hypertensive disorders of pregnancy.
  • The results of the test are not intended to inform the healthcare provider whether or not to change treatment, including medication or hospitalization.

Specimen

  

For 24 hours before specimen collection, the patient should not receive intravenous heparin.

  
Serum
  
1.0 mL
  
0.6 mL
  

Immediately following collection, mix sample thoroughly by gentle inversion, 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  3. Transfer 1.0mL  serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
  4. Freeze

 

  
EDTA plasma
  
  

Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting

  

Frozen (preferred) - 6 months

Refrigerated - 24 hours

Ambient - 24 hours

Performance

  
LabCorp Burlington (486226); R-NX
  
3 - 5 days
  

Homogenous immunoassay

Clinical and Interpretive info

  

See report

Billing

  
83520 x2

Tracking

  
03/21/2024
  
04/29/2024
  
03/21/2024